Database : HANSEN Search on : CLOFAZIMINA/FARMACOL [Subject descriptor] References found : 11 [refine] Displaying: 1 .. 11   in format [Detailed]

page 1 de 1

1 / 11

HANSEN

select to print

Id: 18229 Author: Leonard Wood Memorial*. Title: A statistical analysis of two chemotherapy trials in lepromatous leprosy: II. Interactions among patient variables ..- Source: s.l; s.n; 1978. 4 p. tab. Abstract: Interrelationship among six patient characteristics recorded upon entry the trial were analyzed for 67 patients with lepromatous and near-lepromatous leproay admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of older patients and of patients classified as borderline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological grounds were classified fully lepromatous by the clinical criteria. Measurments of the number of Mycobacterium leprae in the patients made by there methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the hand, and any of the measurments of the numbers of organisms on the other (AU). Descriptors: HANSENIASE DIMORFA/terap HANSENIASE VIRCHOWIANA/terap CLOFAZIMINA/admin CLOFAZIMINA/farmacol CLOFAZIMINA/uso terap RIFAMPINA/uso terap DAPSONA/uso terap HANSENIASE DIMORFA/microbiol HANSENIASE DIMORFA/patol HANSENIASE VIRCHOWIANA/microbiol HANSENIASE VIRCHOWIANA/patol - QUIMIOTERAPIA COMBINADA  DROGAS EM INVESTIGACAO/admin  DROGAS EM INVESTIGACAO/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 00294/s

2 / 11

HANSEN

select to print

Id: 18090 Author: Sampaio, Sebastiao AP; Rivitti, Evandro A. Title: Hanseníase / Leprosy Source: In: Sampaio, Sebastiao AP; Rivitti, Evandro A.Dermatologia. Sao Paulo, Artes Medicas, 2007. p.625-651ilus, graf. Descriptors: HANSENIASE/imunol HANSENIASE/microbiol HANSENIASE/prev HANSENIASE/fisiopatol HANSENIASE/reabil HANSENIASE/terap MYCOBACTERIUM LEPRAE/citol MYCOBACTERIUM LEPRAE/genet MYCOBACTERIUM LEPRAE/imunol MYCOBACTERIUM LEPRAE/fisiol ANTIGENO DE MITSUDA/quim ANTIGENO DE MITSUDA/fisiol - RIFAMPINA/farmacol  RIFAMPINA/uso terap  DAPSONA/farmacol  DAPSONA/uso terap  CLOFAZIMINA/farmacol  CLOFAZIMINA/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: Br191.1; WR100, S47d

3 / 11

HANSEN

select to print

Id: 15629 Author: Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat Title: Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..- Source: s.l; s.n; 2003. 10 p. graf. Abstract: Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU). Descriptors: ANTIINFECCIOSOS/quim ANTIINFECCIOSOS/farmacol ANTIINFECCIOSOS/tox CELULAS CULTIVADAS CLOFAZIMINA/quim CLOFAZIMINA/farmacol CLOFAZIMINA/tox MACROFAGOS/ef drogas TESTES DE SENSIBILIDADE MICROBIANA COMPLEXO MYCOBACTERIUM AVIUM/ef drogas ESTEROIS/quim ACIDO SUCCINICO Limits: ESTUDO COMPARATIVO HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 09082/s

4 / 11

HANSEN

select to print

Id: 13945 Author: Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat Title: Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..- Source: s.l; s.n; 2003. 10 p. graf. Abstract: Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU). Descriptors: ANTIINFECCIOSOS/quim ANTIINFECCIOSOS/farmacol ANTIINFECCIOSOS/tox CLOFAZIMINA/quim CLOFAZIMINA/farmacol CLOFAZIMINA/tox CELULAS CULTIVADAS MACROFAGOS/ef drogas MACROFAGOS/microbiol TESTES DE SENSIBILIDADE MICROBIANA COMPLEXO MYCOBACTERIUM AVIUM/ef drogas ESTEROIS/quim ACIDO SUCCINICO/quim Limits: ESTUDO COMPARATIVO HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 09082/s

5 / 11

HANSEN

select to print

Id: 13354 Author: Holmes, I. B; Banerjee, D. K; Hilson, G. R Title: Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection ..- Source: s.l; s.n; apr. 1976. 5 p. graf. Abstract: Continuous dietary administration of rifampin to mice with an established Mycobacterium leprae footpad infection reduced the bacillary solid ratio, with an estimated survival half-life of 5-6 days. In rifampin-treated immunosuppressed animals the survival half-life of solid bacilli, in the absence of host immunity, was 12-13 days. Clofazimine and B1912 produced a significant effect on solid ratio only after a lag period of apparently 100 days. The rate of action was considerably slower than that of rifampin. Intermittent (once monthly) administration of both drugs produced effects similar to those of continuous administration.(AU). Descriptors: ANTICORPOS ANTIBACTERIAS CLOFAZIMINA/analog CLOFAZIMINA/farmacol CLOFAZIMINA/uso terap IMUNOSSUPRESSAO HANSENIASE/quimioter HANSENIASE/imunol MYCOBACTERIUM LEPRAE/ef drogas MYCOBACTERIUM LEPRAE/imunol FATORES DE TEMPO RIFAMPINA/farmacol RIFAMPINA/uso terap Limits: ESTUDO COMPARATIVO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 01652/s

6 / 11

HANSEN

select to print

Id: 13310 Author: Dubey, G. K; Joglekar, V. K; Hardas, U. D; Chaubey, B. S Title: A study of cell mediated immunity in leprosy ..- Source: s.l; s.n; apr. 1981. 7 p. tab, graf. Abstract: This paper presents a review of 123 cases of leprosy of different clinical types as regards to their status of cellular immunity. These 123 cases included 41 fresh cases, 18 cases of reaction and 64 cases of leprosy taking antileprosy treatment. Out of 41 untreated cases only 11 turned up for follow up and their lymphoblastic transformation was repeated 4 to 6 months after initiating the treatment. It was observed that cell mediated immunity as expressed in terms of percentage of blast cells is definitely depressed in leprosy, most in LL and least in TT. There is a definite increase in the percentage of blast cells after taking antileprosy treatment. The rise in percentage of blast cells and hence cellular immunity is relatively more in patients treated with Lamprene as compared to those treated with DDS. Reactions also have impact over immunity in leprosy. Thus, most of the patients with ENL show higher values for blast percentage as compared to those with lepra reaction. It appears that serial lymphocyte cultures if done in all cases of leprosy undergoing treatment will help in assessment of individual progress.(AU). Descriptors: IMUNIDADE CELULAR/ef drogas HANSENOSTATICOS/farmacol HANSENOSTATICOS/uso terap HANSENIASE/quimioter HANSENIASE/imunol CLOFAZIMINA/farmacol CLOFAZIMINA/uso terap DAPSONA/farmacol DAPSONA/uso terap Limits: HUMANO MASCULINO FEMININO CRIANÇA ADULTO ADOLESCENTE Electronic Medium: http://www.ilsl.br Location: BR191.1; 00771/s

7 / 11

HANSEN

select to print

Id: 13223 Author: Pieters, F. A; Woonink, F; Zuidema, J Title: Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria ..- Source: s.l; s.n; 1988. 4 p. tab, graf. Abstract: In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated. Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23). Correspondingly, the plasma dapsone 24 h after the last dose had fallen significantly from 2.63 to 2.02 mg/l. Clofazimine did not cause change in the pharmacokinetics of dapsone. It was concluded that, although rifampicin had a considerable influence on the pharmacokinetics of dapsone, there is no reason to adjust the dose of dapsone during multidrug therapy of leprosy.(AU). Descriptors: CLOFAZIMINA/admin CLOFAZIMINA/farmacol HANSENIASE/sangue HANSENIASE/quimioter RIFAMPINA/admin RIFAMPINA/farmacol DAPSONA/admin DAPSONA/sangue DAPSONA/farmacocin DAPSONA/uso terap Limits: HUMANO MASCULINO FEMININO ADULTO MEIA-IDADE IDOSO ADOLESCENTE Electronic Medium: http://www.ilsl.br Location: BR191.1; 02067/s

8 / 11

HANSEN

select to print

Id: 10200 Author: O'Connor, Robert; O'Sullivan, J. F; O'Kennedy, Richard Title: The pharmacology, metabolism, and chemistry of clofazimine ..- Source: s.l; s.n; 1995. 24 p. ilus, tab. Descriptors: HANSENIASE MICOBACTERIOSE ABSORÇAO DISPONIBILIDADE BIOLOGICA CROMATOGRAFIA LIQUIDA DE ALTA PRESSAO CLOFAZIMINA CLOFAZIMINA CLOFAZIMINA CLOFAZIMINA SISTEMA IMUNE RELAÇAO ESTRUTURA-ATIVIDADE Location: BR191.1; 06974/s

9 / 11

HANSEN

select to print

Id: 9963 Author: Mendis, Susirith; Somasiri, K. G; Chularatna, W Title: Effect of drug treatment on electroneurological measures of peripheral nerve function in leprosy patients ..- Source: s.l; s.n; 1993. 4 p. tab. Descriptors: CLOFAZIMINA CLOFAZIMINA DAPSONA DAPSONA QUIMIOTERAPIA COMBINADA ELETROFISIOLOGIA HANSENIASE HANSENIASE HANSENIASE DIMORFA HANSENIASE DIMORFA HANSENIASE TUBERCULOIDE HANSENIASE TUBERCULOIDE CONDUÇAO NERVOSA NERVOS PERIFÉRICOS NERVOS PERIFÉRICOS TEMPO DE REAÇAO RIFAMPINA RIFAMPINA HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA Location: BR191.1; 06607/s

10 / 11

HANSEN

select to print

Id: 9209 Author: Mendes, Abraao Garcia; Campos, Wesley Ribeiro; Orefice, Fernando; Monteiro, Lilian Grace; Sucena, Maria Aparecida Title: Impregnacao sui generis conjuntivo escleral por clofazimina em um paciente portador de hanseniase Impregnation sui generis of the conjunctiva and sclera by clofazimine in a carrier Hansen's disease- Source: s.l; s.n; 1994. 8 p. ilus. Descriptors: CONJUNTIVA ESCLERA HANSENIASE CLOFAZIMINA CLOFAZIMINA Location: BR191.1; 06173/s

11 / 11

HANSEN

select to print

Id: 6703 Author: Banerjee, D. K; Ellard, G. A; Gammon, Patricia T; Waters, M. F. R Title: Some observations on the pharmacology of clofazimine (B663) ..- Source: s.l; s.n; 1974. 5 p. . Descriptors: HANSENIASE HANSENIASE - CLOFAZIMINA  CLOFAZIMINA  CLOFAZIMINA Location: BR191.1; 03831/s

---

page 1 de 1

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information